Glioblastoma vs cerebral metastasis

Differentiating a glioblastoma (GBM) from a cerebral metastasis is a frequent challenge, with profound surgical, workup and treatment implications. Unfortunately distinguishing between the two entities is not always straightforward. 

This article addresses helpful imaging features to aid in distinguishing between these two entities preoperatively. For a general discussion of cerebral metastases and glioblastoma (GBM) please refer to their respective articles. 

Probably the most helpful feature of cerebral metastases, other than known rampant systemic metastatic disease, is their multiplicity, with approximately three-quarters of patients having multiple lesions at presentation 1. However, that means that the remaining 25% of patients present with a single lesions, and in many instances no known systemic illness. To make matters worse it is not uncommon for GBMs to present with multiple enhancing foci. 

The best clue in distinguishing between the two is that in the vast majority of cases of GBM with multiple areas of enhancement, they are all embedded within the one area of FLAIR signal abnormality, or linked by abnormal FLAIR signal. This is termed multifocal glioblastoma.

If the enhancing lesions are completely separate, not linked by FLAIR signal abnormality they most likely represent cerebral metastases, as this pattern of enhancement is very uncommon in GBM, and is called multicentric glioblastoma

Cerebral metastases have a predilection for the grey-white matter junction, and less frequently involve the deeper brain. They tend not to involve the periventricular white matter and rarely extend into the corpus callosum

In contrast, GBM tends to be centered on the subcortical white matter, with frequent extension and spread along the subependymal tissues. Invasion and expansion of the corpus callosum is also frequently encountered. 

Cerebral metastases are typically spheres of foreign tissue, relatively well circumscribed and separate from the adjacent brain parenchyma. They are surrounded by vasogenic oedema which can vary greatly in amount, from minimal to vast. Importantly, other than the center of the lesions, which frequently demonstrate necrosis and/or haemorrhage, there are not adjacent areas of non-enhancing tumour. This is particularly helpful in peripheral lesions which involve the cortex. Gliomas often have components that demonstrate cortical expansion without enhancement (non-enhancing "peritumoural" component *). 

Gliomas tend to have a more complex shape (less spherical), however even with semi-automated computer assisted interpretation of shape, this difference is difficult to exploit to increase accuracy 10.

Dynamic susceptibility contrast (DSC) MR perfusion can be helpful in distinguishing between cerebral metastases and glioblastoma 2,3. The utility stems from two underlying differences in the vascularity of metastases and primary brain tumours.

Firstly, the vascularity of the enhancing tumour component can be quite different. Metastases have vessels that resemble those of the tissue of origin, and as such lack any discernible blood brain barrier. In contrast, glioma vessels, although often abnormal, usually have some remaining blood brain barrier structure 2

Secondly the vascularity of normal brain surrounding a metastases is histologically normal, and non-enhancing high T2 signal is due to vasogenic oedema. In contrast, the non-enhancing region of high T2 signal surrounding a glioma often represent non-enhancing tumour, and thus will also have abnormal vessels 2

Two metrics that are useful in distinguishing between the two, require assessment of signal intensity-time curves 2,3

  • peak height
    • maximal signal intensity drop from the precontrast baseline during the bolus phase of the first pass of gadolinium
    • correlates with capillary density and rCBV
    • elevated in peri-enhancing high T2 signal parenchyma in gliomas  representing presence of abnormal blood vessels 2
  • percentage signal intensity recovery
    • percentage of signal intensity recovered relative to the precontrast baseline at the end of the first pass
    • correlates with degree of capillary permeability and contrast leakage
    • higher in enhancing component of tumours, representing more intact BBB in gliomas 2

Arterial spin labeled (ASL) perfusion has also shown increased cerebral blood flow (CBF) in the peri-enhancing high T2 signal brain of gliomas 3

MR spectroscopy is another potentially useful technique in distinguishing metastases from glioblastomas, although it is in practice by no means perfect as it requires careful placement of voxels relative to the enhancing and non-enhancing components. 

The most useful region to interrogate is the non-enhancing high T2 signal region adjacent to the enhancing component. In this region gliomas tend to demonstrate features of tumour infiltration (elevated choline) whereas metastases demonstrate normal or somewhat depressed traces 6-9. Traces obtained from the solid enhancing component are more difficult to interpret and studies have reported variable findings. 

  • choline peak
    • non-enhancing "peritumoral" component *: elevation of Cho/Cr and Cho/NAA suggests glioma and reflects tumour infiltration 6,7
      • Cho/Cr ratio > 1.24: sensitivity 100%, specificity 88.9%, positive (PPV) 80.0%, and negative predictive values (NPV)  100% 7
      • Cho/NAA ratio > 1.11: sensitivity 00%, specificity 91.1%, PPV 83.3%, and NPV 100% 7
    • solid enhancing component: elevated in both glioblastoma and metastasis, reflecting high cellular membrane turnover 4
  • NAA peak
    • solid enhancing component: if present helpful (provided voxel is entirely intralesional) and indicated glioblastoma 4
  • lipids peak
    • solid enhancing component: is unhelpful if present as it merely indicates cellular necrosis in both glioblastoma or metastasis
    • solid enhancing component: high lipid/Cr ratio suggests metastasis 5

* the term "peri-tumoural" is unfortunate as it is now well known that in gliomas tumour cells extend well beyond the enhancing margins, and as such what is being referred to is non-enhancing tumour or "peri-enhancement"

Share article

Article Information

rID: 43344
Section: Approach
Synonyms or Alternate Spellings:
  • GBM vs cerebral metastasis

Support Radiopaedia and see fewer ads

Updating… Please wait.
Loadinganimation

Alert accept

Error Unable to process the form. Check for errors and try again.

Alert accept Thank you for updating your details.